MET treatment also increased the proportion of apoptotic drug‐sensitive and drug‐resistant breast cancer cells, induced cleavage of caspase‐3, increased BAX expression and decreased BCL2 expression (Figure 2). Here, BCL2 is linked to breast carcinoma.